A Look At Zymeworks (ZYME) Valuation As AACR 2026 ADC Data Draws Investor Attention

Simply Wall St.04-20

Zymeworks (ZYME) has put its antibody drug conjugate pipeline in the spotlight, announcing six new preclinical data posters and an upcoming Phase 1 ZW191 oral presentation at the AACR Annual Meeting ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628479369?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-20 01:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628479369","market":"sg","top_or_hot":-1,"title":"A Look At Zymeworks (ZYME) Valuation As AACR 2026 ADC Data Draws Investor Attention","media":"Simply Wall St.","content":"<div>\n<p>Zymeworks (ZYME) has put its antibody drug conjugate pipeline in the spotlight, announcing six new preclinical data posters and an upcoming Phase 1 ZW191 oral presentation at the AACR Annual Meeting ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/a-look-at-zymeworks-zyme-valuation-as-aacr-2026-adc-data-dra\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Zymeworks (ZYME) Valuation As AACR 2026 ADC Data Draws Investor Attention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Zymeworks (ZYME) Valuation As AACR 2026 ADC Data Draws Investor Attention\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-20 01:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/a-look-at-zymeworks-zyme-valuation-as-aacr-2026-adc-data-dra><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zymeworks (ZYME) has put its antibody drug conjugate pipeline in the spotlight, announcing six new preclinical data posters and an upcoming Phase 1 ZW191 oral presentation at the AACR Annual Meeting ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/a-look-at-zymeworks-zyme-valuation-as-aacr-2026-adc-data-dra\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4231","symbol_name":"零售房地产信托","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/a-look-at-zymeworks-zyme-valuation-as-aacr-2026-adc-data-dra","article_id":"2628479369","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/a-look-at-zymeworks-zyme-valuation-as-aacr-2026-adc-data-dra","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2628479369","pubTimestamp":1776618435,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Zymeworks (ZYME) has put its antibody drug conjugate pipeline in the spotlight, announcing six new preclinical data posters and an upcoming Phase 1 ZW191 oral presentation at the AACR Annual Meeting 2026.\nSee our latest analysis for Zymeworks.\nThe recent AACR pipeline update and new executive appointments come after a strong run in the stock, with a 30 day share price return of 19.21% and a 1 year total shareholder return of 141.11%. However, the 5 year total shareholder return of a 1.94%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","ADC":"艾格里房产","BK4139":"生物科技","ZYME":"ZYMEWORKS INC (US)"},"translate_title":"随着AACR 2026 ADC数据引起投资者关注，Zymeworks(ZYME)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1.5,"ZYME":1.5},"content_text":"Zymeworks (ZYME) has put its antibody drug conjugate pipeline in the spotlight, announcing six new preclinical data posters and an upcoming Phase 1 ZW191 oral presentation at the AACR Annual Meeting 2026. See our latest analysis for Zymeworks. The recent AACR pipeline update and new executive appointments come after a strong run in the stock, with a 30 day share price return of 19.21% and a 1 year total shareholder return of 141.11%. However, the 5 year total shareholder return of a 1.94% loss shows how recent momentum contrasts with a softer longer term picture. If Zymeworks’ recent move has you thinking about what else is out there in healthcare, it could be worth scanning other oncology and biotech names through 36 healthcare AI stocks. With Zymeworks trading at US$27.80, a 37% intrinsic discount and a 44% gap to the average analyst target suggest upside on paper. However, after a 141% 1-year return, the question is whether there is still a genuine opportunity here or if future growth is already priced in. AdvertisementMost Popular Narrative: 30.6% Undervalued Against the last close at $27.80, the most followed narrative points to a fair value of about $40.08, putting a clear gap between price and modeled worth.  The analysts have a consensus price target of $40.08 for Zymeworks based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $58.0, and the most bearish reporting a price target of just $31.0.  Read the complete narrative. Curious what has to happen for that gap to close? The narrative leans on faster revenue expansion, a swing from losses to profits, and a rich future earnings multiple. Result: Fair Value of $40.08 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there is still real execution risk with heavy dependence on milestone and royalty payments, and key trials like HERIZON GEA-01 and ZW191 carrying clear binary outcomes. Find out about the key risks to this Zymeworks narrative. Next Steps With all this optimism and risk in the mix, it helps to look under the hood yourself and decide if the rewards stack up. To see what is getting investors excited and weigh those potential upsides against your own expectations, take a closer look at the 3 key rewards. Looking for more investment ideas? If Zymeworks is on your radar, do not stop there. Widen your watchlist with a few focused stock ideas that could sharpen your next investing move.  Spot potential value opportunities early by checking companies highlighted in the screener containing 23 high quality undiscovered gems. Prioritise financial resilience by scanning stocks in the solid balance sheet and fundamentals stocks screener (42 results). Target dependable income streams by reviewing companies featured as 12 dividend fortresses.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zymeworks might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628479369","isCrawlerRequest":true}